| Y |
| Yañez L. |
- |
Recombinant Factor VIIa as hemostatic agent in acquired von Willebrand disease |
| Yadigarova Z. |
- |
Interleukin 1b modulates platelet function |
| Yagi H. |
- |
Localization and activity of ecto-ATP diphosphohydrolase/CD39 in human tissues |
| |
- |
Mutations of ADAMTS13 gene in four Japanese families with Upshaw–Schulman syndrome |
| Yagihara T. |
- |
Successful argatroban-anticoagulant management for left ventricular assist system implantation in two patients with heparin-induced thrombocytopenia type II |
| Yahya H. |
- |
Increased thrombophilic abnormalities in patients with cranial dural arteriovenous fistulae |
| Yakunina L. N. |
- |
The experience of treatment of children with hemostasis system pathology treatment with recombinant factor VII NovoSeven |
| |
- |
Idiopathic thrombocytopenic purpura at children, associated with a virus of rubella |
| |
- |
Cases of development of an idiopathic thrombocytopenic purpura at children associated with introduction of a tuberculin |
| |
- |
Plasma glycocalicin level in diagnosis of the idiopathic thrombocytopenic purpura (ITP) in children |
| Yalin S. |
- |
Erythrocytic membrane proteins in sickle cell anemia in crisis and steady state |
| Yamada K. |
- |
A dose–response study of a recombinant human soluble thrombomodulin (ART-123) for prevention of venous thromboembolism after unilateral total hip replacement |
| |
- |
Phase I study of a novel recombinant human soluble thrombomodulin, ART-123 |
| Yamaji K. |
- |
Endothelial anticoagulant thrombomodulin (TM) as a natural anti-inflammatory, ‘HMG1 blocker’, inhibits pro-inflammatory cell activation |
| Yamaji K. |
- |
Activated protein C as a proteolytically activable antioxidant, anticoagulant protein |
| Yamaji K. |
- |
2-Arachidonoylglycerol (2-AG) endocannabinoids, induces platelets conjugation with neutrophils (Platelet Satellitism) in vitro |
| |
- |
The natural anticoagulant Thrombomodulin has radical scavenging activity and acts as an antioxidant C-type lectin |
| Yamakuchi M. |
- |
The natural anticoagulant Thrombomodulin has radical scavenging activity and acts as an antioxidant C-type lectin |
| Yamamoto J. |
- |
Effect of a nitric oxide donor on platelet reactivity and spontaneous thrombolysis in patients with chronic renal failure |
| Yamamoto K. |
- |
Ryudocan (syndecan-4) deficiency increases susceptibility to LPS-induced shock in mice |
| Yamamoto J. |
- |
GTT: A comprehensive in vitro haemostasis test, assessing platelet function, coagulation and thrombolytic activity from a single native blood sample |
| Yamamoto H. |
- |
Platelet recruitment in vivo to injured blood vessels is not prevented by GPIIb/IIIa antagonism |
| Yamamoto K. |
- |
Aging and obesity augment the stress-induced expression of tissue factor gene in the mouse |
| Yamamoto J. |
- |
Various ratio of n-3/n-6 polyunsaturated fatty acid alters the tendency of thrombosis and progress of atherosclerosis in apoE-/- LDLR-/- double knockout mouse |
| |
- |
A new global thrombosis test (GTT) shows impaired spontaneous thrombolytic activity in elderly and in habitual smokers |
| |
- |
Effect of ADP P2Y12 receptor inhibition on thrombosis and bleeding measured using guinea pigs |
| Yamamoto J. |
- |
Impaired flow-mediated vasodilation in vivo and reduced shear-induced platelet reactivity in vitro in response to nitric oxide in prothrombotic, stroke-prone spontaneously hypertensive rats |
| Yamanouchi M. |
- |
Hemophilia A gene therapy using the third-generation lentiviral vector – Mouse model |
| Yamashita T. |
- |
A new global thrombosis test (GTT) shows impaired spontaneous thrombolytic activity in elderly and in habitual smokers |
| Yamashita T. |
- |
Various ratio of n-3/n-6 polyunsaturated fatty acid alters the tendency of thrombosis and progress of atherosclerosis in apoE-/- LDLR-/- double knockout mouse |
| Yamashita T |
- |
Various ratio of n-3/n-6 polyunsaturated fatty acid alters the tendency of thrombosis and progress of atherosclerosis in apoE-/- LDLR-/- double knockout mouse |
| Yamashita T. |
- |
GTT: A comprehensive in vitro haemostasis test, assessing platelet function, coagulation and thrombolytic activity from a single native blood sample |
| Yamashita A. |
- |
Combination of increased vascular thrombogenesity and blood flow alteration promote obstructive thrombus formation in rabbit femoral artery |
| Yamashita T. |
- |
Effect of a nitric oxide donor on platelet reactivity and spontaneous thrombolysis in patients with chronic renal failure |
| Yamauchi T. |
- |
Neonatal injection of human factor VIII induces immune tolerance in murine hemophilia A |
| Yamazaki T. |
- |
H1299R mutation results in retention of mutant factor V molecule in the Golgi complex: a possible novel type of quantitative defect |
| Yamazaki M |
- |
Is an antithrombin substance (aFIIa) more hemorrhagic compared with an anti-factor Xa (aFXa) aent?: Differential inhibitory effects of these two agents against platelet activation |
| Yamazaki T. |
- |
Inefficient secretion and intracellular degradation of factor V |
| Yamazaki T. |
- |
Functional properties of recombinant factor Va mutated in a potential calcium-binding site |
| |
- |
Factor V New Brunswick: Ala221Val associated with FV deficiency reproduced in vitro and functionally characterized |
| Yamazaki M. |
- |
Three novel point mutations that cause severe factor XI deficiency in two unrelated Japanese families |
| Yamazaki T. |
- |
Functional characterization of recombinant factor V molecules mimicking the R2-haplotype |
| Yamazaki M. |
- |
Rituximab reduces anti-phospholipid antibody (APA) titers and improves hypercoagulability in patients with anti-phospholipid syndrome (APS) |
| Yamazaki S. |
- |
Mechanism of decreased plasma von Willebrand Factor-cleaving metalloproteinase activity in patients with collagen vascular disease |
| Yanagisawa Y. |
- |
Natto Bacillus (Bacillus subtilis natto) as an oral fibrinolytic agent |
| Yang X. |
- |
Soluble platelet GPV: a new marker of thrombosis status |
| |
- |
Soluble platelet GPV: a new marker of thrombosis status |
| Yang L. |
- |
The fourth epidermal growth factor-like domain of thrombomodulin interacts with the basic exosite of protein C |
| Yang H. |
- |
Structural elements in tissue-type plasminogen activator contributing to its storage in primary endothelial cells |
| Yang J. |
- |
Similar molecular interactions of factor VII and factor VIIa with the tissue factor region that allosterically regulates enzyme activity |
| Yang P. |
- |
Studies of the relationship between elevated factor VIII level and ischemic stroke in China |
| Yang X. |
- |
The omega-loop within the Gla domain (G4–Q11) and the EGF2 domain (C88–C124) of factor IXa are both essential for the assembly of the FX activating complex on activated platelets |
| Yang H. |
- |
Effect of simvastatin on the production of tissue-type plasminogen activator in endothelial cells |
| Yang A. Y. |
- |
The factor V Leiden mutation results in the in vivo loss of a critical FV anticoagulant function |
| Yang L. |
- |
Role of basic residues of proexosite 1 on prothrombin in the prothrombinase complex |
| Yang H. |
- |
Effects of simvastatin on secretagogue-induced exocytosis from endothelial cells |
| Yang H. |
- |
High-level transgene expression of lentivirus-transduced human endothelial cells |
| Yap C. |
- |
Role of the Type Ia PI 3-kinase p110beta isoform in integrin alpha(IIb)beta(3) bi-directional signaling |
| Yap C. L. |
- |
Phosphoinositide 3-kinase beta (PI3Kb): a novel target for antithrombotic therapy |
| Yap C. L. |
- |
Integrin aIIbb3 outside-in calcium signals sustain platelet–fibrinogen interactions under flow |
| Yarat A. |
- |
Effects of 6,7-dihydroxy-3-phenylcoumarin and warfarin on thromboplastin induced experimental disseminated intravascular coagulation |
| Yarmohammadi H. |
- |
Inherited coagulation disorders in southern Iran |
| |
- |
Inherited coagulation disorders in southern Iran |
| Yarom I. |
- |
Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study |
| Yarova H. |
- |
A transgenic mouse model demonstrates the efficacy of Factor VIII ectopically expressed in platelets for Haemophilia A treatment |
| Yarranton H. |
- |
Venous thromboembolism (VTE) associated with the management of acute thrombotic thrombocytopenic purpura (TTP) |
| |
- |
The effect of pathogen inactivation treatment processes on VWF cleaving protease, VWF:Ag and protein S levels in blood components used in therapeutic plasma exchange for thrombotic thrombocytopenic purpura |
| Yassin J. |
- |
Evaluation of platelet function analyzer (PFA-100), whole blood (WB), and platelet rich plasma (PRP) aggregation methods in detecting aspirin resistance |
| Yasumuro Y. |
- |
Mechanism of decreased plasma von Willebrand Factor-cleaving metalloproteinase activity in patients with collagen vascular disease |
| Yatagai C. |
- |
Isolation and administration effect of fibrinolysis accelerating substance (FAS) in the fermented soybean food, natto |
| |
- |
Natto Bacillus (Bacillus subtilis natto) as an oral fibrinolytic agent |
| Yates J. |
- |
Cell lines expressing recombinant platelet membrane glycoprotein isoforms as tools for the characterization of antibodies against low frequency alloantigens in neonatal alloimmune thrombocytopenia |
| Yatomi Y. |
- |
Interaction of the glycoprotein (GP) Ib-IX/V complex with the platelet collagen receptor GPVI |
| |
- |
Remnant-like lipoprotein particles potentiate platelet activation under high shear stress assessed by the ‘collagen column’, filled with collagen-coated small beads |
| |
- |
Differential role of phosphatidylinositol 3-kinase in glycoprotein Ib-mediated platelet activation |
| |
- |
Sphingosine 1-phosphate-related metabolism in the blood |
| |
- |
Mechanisms of platelet retention in the collagen-coated bead columns |
| |
- |
Platelet endothelial cell adhesion molecule-1 (PECAM-1) of platelets is cleaved under high shear stress |
| Yatsenko E. A. |
- |
The principles of therapy of hemorrhagic vasculitis at children |
| Ye B. |
- |
Development of small molecule compounds that inhibit PAI-1 activity in vitro and in vivo |
| Ye X. |
- |
Clinical thrombolytic trial of a new type of tissue-plasminogen activator in patients with acute stroke |
| Yee T. T. |
- |
Combined modality inhibitor eradication in a patient with mild hemophilia A and comparison of methods of inhibitor monitoring |
| Yegneswaran S. |
- |
Amino acid sequences in human prothrombin that interact with factor Xa and factor Va |
| Yegneswaran S. |
- |
Downregulation of Factor IXa in the Factor Xase complex by protein Z-dependent protease inhibitor (ZPI) |
| Yegneswaran S. |
- |
Amino acid sequences in factor Xa that bind prothrombin and factor Va |
| Yegneswaran S. |
- |
Neutral and charged lipids in factor Va inactivation |
| Yeguiayan J. M. |
- |
Risk factors of major hemorrhages during treatment of acute DVT: results from 5 randomized trials |
| Yehia H. |
- |
Ultrastructural changes in platelets after surgical manipulations in pigs liver |
| Yen M. H. |
- |
Inhibitory effects of andrographolide on lipopolysaccharide-induced tissue factor expression in human monocytic THP-1 cells |
| Yeo E. |
- |
Recombinant FVIIa: correction of thrombocytopenic defects in whole blood clotting model |
| |
- |
Assessing rFVIIa coumadin reversal effect with whole blood coagulation analyzer |
| Yeong S. H. |
- |
Heat shock treatment induces stress tolerance in platelets |
| Yeun E. |
- |
Screening for the Factor V Leiden mutation with a Russell's viper venom-based clotting test |
| Yevdokimova N. |
- |
N-terminal disulfide knot of fibrin increases the accumulation of hyaluronic acid in the pericellular matrix of human umbilical vein endothelial cells |
| Yi Q. |
- |
Anti-phospholipid antibodies in ischemic stroke |
| |
- |
Platelet endothelial cell adhesion molecule-1 (PECAM-1) of platelets is cleaved under high shear stress |
| Yi S. E. |
- |
Economic modeling of full-length anti-hemophilic factor (recombinant), plasma/albumin-free method (rAHF-PFM), vs. B-domain deleted rFVIII (BDDrFVIII) in previously treated patients (PTPs) with hemophilia A |
| Yi S. |
- |
Clinical evaluation of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in surgical settings |
| Yi H. |
- |
Aging and obesity augment the stress-induced expression of tissue factor gene in the mouse |
| Yilmaz E. |
- |
HR2 haplotype (4070G-A (FV1299 His-Arg)) in Turkish thrombosis patients |
| Yilmaz S. |
- |
Protein C, S and antithrombin III levels in patients with acute mechanical valve thrombosis |
| Yilmaz S. |
- |
Life threatening mediastinal-retroperitoneal hemorrhage in a child with moderate hemophilia A and high titer inhibitor: successful management with recombinant activated factor VII |
| Yilmaz E. |
- |
Life threatening mediastinal-retroperitoneal hemorrhage in a child with moderate hemophilia A and high titer inhibitor: successful management with recombinant activated factor VII |
| Yin X. |
- |
Evidence for extracellular signal-regulated kinase 1/2 activation by thrombin that is independent on epidermal growth factor receptor transactivation in vascular smooth muscle cells |
| Ylaenne J. |
- |
Human, conformation-specific, anti-GPIIb/IIIa (aIIbb3) single-chain antibodies generated by differential phage-display: a new generation of platelet inhibitors specific for the activated GPIIb/IIIa receptor? |
| Yndestad A. |
- |
Interleukin-7-mediated inflammation in unstable angina – possible role of chemokines and platelets |
| Yngen M. |
- |
Thrombin activatable fibrinolysis inhibitor (TAFI) and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications |
| |
- |
Enhanced platelet and leukocyte activation by strenuous exercise in type I diabetes mellitus |
| Yngen M. |
- |
Platelet function and inflammatory markers in patients with type 1 diabetes with and without microvascular complications |
| Yngen M. |
- |
Enhanced leukocyte-platelet cross-talk in type 1 diabetes mellitus |
| Yohal D. |
- |
Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study |
| Yokochi M. |
- |
Correlation between anti-coagulant therapeutic range and Prothrombin Fragment 1 + 2 in Japanese patients with Cardioembolic Stroke |
| Yoneda K. |
- |
Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747, a novel P2Y12 receptor antagonist |
| Yonekawa K. E. |
- |
A proposed mechanism for reduced bleeding of direct thrombin inhibitors as compared to heparin as measured by thromboelastography |
| Yonemitsu Y. Y. |
- |
Recombinant sendai virus-mediated intramuscular gene transfer of FGF-2 restores collateral blood perfusion of chronically ischemic rabbit hind limb, and inhibits neointimal hyperplasia of autologous femoral vein grafts |
| Yonemitsu Y. |
- |
Platelet-derived growth factor receptor-alpha signaling is required for therapeutic angiogenesis induced by fibroblast growth factor-2 |
| |
- |
Involvement of VEGF-C/flt-4 system in therapeutic angiogenesis of FGF-2 gene transfer in murine ischemic hind limb |
| Yong X. |
- |
Lipid Phosphate Phosphatase 1 (LPP1) regulates lysophosphatidic acid signaling in platelets |
| Yoo S. H. |
- |
A collaborative study to establish a Korean standard for factor VIII : C concentrate |
| |
- |
A collaborative study to establish a Korea National Biological Standard for antithrombin III concentrate |
| Yoo W. D. |
- |
A common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its association with a haplotype in the Korean population |
| Yoon S. S. |
- |
A common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its association with a haplotype in the Korean population |
| |
- |
Polymorphisms of 5,10-methylenetetrahydrofolate reductase gene and risk of Korean acute leukemia |
| Yoshida H. |
- |
Interaction of CD47 with SHPS-1 negatively regulates platelet function |
| Yoshida W. B. |
- |
Prophylaxis of deep vein thrombosis after lower extremity amputation: comparison of low molecular weight heparin with unfractionated heparin |
| Yoshida T. |
- |
Is an antithrombin substance (aFIIa) more hemorrhagic compared with an anti-factor Xa (aFXa) aent?: Differential inhibitory effects of these two agents against platelet activation |
| Yoshioka A. |
- |
M-thrombin (Tris-coupled thrombin) is a novel potent agonist of platelet activation with minimum effect on clot formation |
| |
- |
Factor V C2 domain contains major binding site for thrombin |
| Yoshioka S. |
- |
EF6265: a new synthetic, potent and selective plasma CPB/TAFIa inhibitor |
| Yoshioka A. |
- |
The hemostatic effectiveness of regular infusions of factor VIII concentrates in hemophilia A patients with high responder inhibitors |
| |
- |
Hemophilia A gene therapy using the third-generation lentiviral vector – Mouse model |
| |
- |
Activated factor VII enhances whole blood fibrinolysis due to urokinase-type plasminogen activator |
| |
- |
Blood coagulation during mural throbogenesis under whole blood flow conditions with high shear rates |
| |
- |
Characterization of anti-factor VIII antibodies using Time-Resolved Fluoroimmunoassay |
| |
- |
Mural thrombus generation in classic hemophilia under whole blood flow conditions |
| Youman P. |
- |
An economic evaluation of the costs and benefits of heparin rationalisation in a UK hospital |
| Young L. |
- |
Correction of coagulation, as measured by the thromboelastogram, with low dose recombinant VIIa treatment in a patient with a factor VIII inhibitor |
| Young M. |
- |
The Veterans Affairs Cooperative Studies Program's ‘80+ Hemorrhagic Cohort Study |
| Young G. |
- |
A proposed mechanism for reduced bleeding of direct thrombin inhibitors as compared to heparin as measured by thromboelastography |
| Young J. |
- |
Increased factor XIII B and decreased factor XIII A subunit antigen levels in insulin resistant South Asian patients with ischaemic stroke |
| Young N. L. |
- |
Development of the Canadian hemophilia outcomes – Kids Life Assessment Tool (CHO-KLAT) |
| Young G. |
- |
Paradoxical effect of Factor XIII replacement on clot initiation |
| Young J. |
- |
Increased coagulation factor XIII B subunit antigen and factor XIII biotin activity is associated with family history of stroke in South Asians |
| Young L. |
- |
The rate of thrombus resolution following treatment of DVT is related to the site and the precipitating cause of thrombosis |
| Younis J. |
- |
Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study |
| Youseffian T. |
- |
Platelets endocytosis of HIV and S. aureus is enhanced by activation and occurs in specific compartment, site of subsequent degranulation |
| Yu Y. Y. |
- |
A G-to-A mutation at -33 position in the promoter region of thrombomodulin gene and non-O blood group are associated with idiopathic venous thromboembolism: Taiwan Thrombophilia Study |
| Yu I. S. |
- |
Consequences of expression of hepsin in murine vascular systems |
| Yu A. |
- |
Identification of amino acids in antiplasmin involved in the noncovalent ‘lysine-binding site’ dependent interaction with plasmin |
| Yu K. |
- |
Thrombin-activatable fibrinolysis inhibitor is not associated with the occurrence of ischemic stroke |
| Yuan Y. |
- |
Integrin aIIbb3 outside-in calcium signals sustain platelet–fibrinogen interactions under flow |
| Yuan Q. P. |
- |
Expression of recombinant human gla-domainless factor X (gdFX) in the baculovirus: assessing substrate recognition by the intrinsic tenase complex |
| Yuan Y. |
- |
PLC g-dependent GPIb signaling following platelet adhesion to von Willebrand factor through a pathway distinct from FcR g chain and FcgRIIA |
| |
- |
Phosphoinositide 3-kinase beta (PI3Kb): a novel target for antithrombotic therapy |
| Yudkin J. S. |
- |
Polymorphisms in the thrombomodulin gene as risk factors for myocardial infarction (HIFMECH study) |
| Yuen W. K. |
- |
Coagulation and fibrinolysis during the menstrual cycle and the effects of increased body mass index |
| |
- |
Plasminogen activators, plasminogen activator inhibitor-1 and D-dimer levels in gynecological cancer |
| Yun Y. |
- |
Inhibitory mechanism of rat aortic vascular smooth muscle cell proliferation by NQ12, a novel antithrombotic agent |
| |
- |
The anti-platelet activity of J78 is mediated mainly by inhibition of arachidonic acid metabolism |
| Yun T. |
- |
A common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its association with a haplotype in the Korean population |
| Yun T. H. |
- |
Factor XI-activation by thrombin on activated platelets requires both anion binding exosites I and II |
| Yurchuk S. |
- |
Influence of peloidotherapy on hemostasis, cytokines productions and lymphocyte-platelet adhesion |
| Yusen R. |
- |
Non-invasive detection of proximal DVT using bilateral compression ultrasound: methodology for the EXCLAIM study |
| |
- |
Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with prolonged periods of immobilisation: the EXCLAIM study |
| Yusuke M. |
- |
Hypercoagulation and elevated blood pressure induced by phosphatidylserine/phosphatidylcholine microvesicles in pregnant mice can be suppressed by heparin and annexin V |
| Yuzbasioglu S. |
- |
Erythrocytic membrane proteins in sickle cell anemia in crisis and steady state |
